Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma.

Nat Commun · 2023 · PMC10017680 · PMID 36922497

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

There were differences in PFS in patients according to PTEN status by IHC (PTEN lost median 3.6 months [95% CI 1.6-not reached] vs PTEN retained 1.8 months [95% CI 0.5–3.6]; p = 0.07) in C2, which did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.